In the news
View the latest updates from the 59 North team and our clients below:
01
Jun
2026
In Vivo: The Nighttime Evidence Gap – How Passive Monitoring Could Reshape Trial Endpoints
26
May
2026
Biospace: 4 troubled targets that have thwarted biopharma
26
May
2026
ICT: Beyond the Clinic – Continuous Symptom Monitoring as the New Gold Standard
22
May
2026
BioPitch: Why One-carbon’s Ana Slipicevic Puts Data Before the Pitch
15
May
2026
GEN: AI-Optimized Cas12l Gene Editor Offers Compact Cas9 Alternative
15
May
2026
Scrip: With Selective Targeting, HaemaLogiX Eyes Crowded Multiple Myeloma Space
13
May
2026
Drug Discovery World: A novel approach to HER2-targeted radiotherapy
13
May
2026
Labiotech: TIL therapies – the impact on cancer research
30
Apr
2026
Clinical Trial Vanguard: The Disease-Modification Bet in Pulmonary Arterial Hypertension
30
Apr
2026
Drug Development & Delivery: Affibody Molecules; A Versatile Approach to Radiopharma
28
Apr
2026
Dicot Pharma intends to carry out an 80% already secured rights issue of SEK 210 million
22
Apr
2026
CuraCell Strengthens Board of Directors with Appointment of Thomas Jaecklin and Martin Forster
21
Apr
2026
Mergermarket: CuraCell plans EUR 25m round to fund cancer cell therapy
15
Apr
2026
In Vivo: How An Italian Ocular AAV Innovator Is Bucking The Trend In Gene Therapy
13
Apr
2026
Pink Sheet: Regulatory Alignment Helps Cereno Chart Faster, Cheaper Route For CS014
13
Apr
2026
AgTech Navigator: BetterSeeds and Caszyme target tissue culture bottleneck with viral delivery of ultra‑compact CRISPR tools
07
Apr
2026
BioWorld: One-carbon has new approach to starving tumors of nucleotides
One-carbon CEO Ana Slipicevic sat down with Anette Briendl of BioWorld at the recent BIO Europe Spring conference to discuss the company's first-in-class inhibitor of MTHFD1/...